Reducing hypoxia and inflammation during invasive pulmonary aspergillosis by targeting the Interleukin-1 receptor

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Gresnigt, Mark S ^a,b   Rekiki, Abdessalem ^c   Rasid, Orhan ^a   Savers, Amélie ^d   Jouvion, Grégory ^a   Dannaoui, Eric ^e   Parlato, Marianna ^f   Fitting, Catherine ^a   Brock, Matthias ^d   Cavaillon, Jean Marc ^a   Van De Veerdonk, Frank L ^b   Ibrahim Granet, Oumaïma ^a  

^a INSTITUT PASTEUR   (France)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BIOASTER   (France)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f IMAGINE INSTITUTE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAR9 PROTEIN, MOUSE; CARBONATE DEHYDRATASE IX; CHEMOKINE RECEPTOR CXCR2; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; DEFICIENCY; DISEASE MODEL; DRUG EFFECT; GENETICS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INVASIVE ASPERGILLOSIS; METABOLISM; MOUSE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANIMALS; CARBONIC ANHYDRASE IX; CELL HYPOXIA; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOCOMPROMISED HOST; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INVASIVE PULMONARY ASPERGILLOSIS; MICE; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-8B; TREATMENT OUTCOME;

EID: 84971216351     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26490     Document Type: Article

References (70)

1. Brown, G. D. et al. Hidden killers: human fungal infections. Science translational medicine 4, 165rv113, doi: 10.1126/scitranslmed.3004404 (2012).
2. Kontoyiannis, D. P. et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50, 1091-1100, doi: 10.1086/651263 (2010).
3. Garcia-Vidal, C., Upton, A., Kirby, K. A. & Marr, K. A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time afer transplantation. Clin Infect Dis 47, 1041-1050 (2008).
4. Marr, K. A., Carter, R. A., Boeckh, M., Martin, P. & Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100, 4358-4366 (2002).
5. Lewis, R. E. & Kontoyiannis, D. P. Invasive aspergillosis in glucocorticoid-treated patients. Medical mycology: ofcial publication of the International Society for Human and Animal Mycology 47 Suppl 1, S271-281, doi: 10.1080/13693780802227159 (2009).
6. Ibrahim-Granet, O. et al. In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune efector cells in defense against invasive aspergillosis. BMC Microbiol 10, 105 (2010).
7. Grahl, N. et al. In vivo hypoxia and a fungal alcohol dehydrogenase infuence the pathogenesis of invasive pulmonary aspergillosis. PLoS pathogens 7, e1002145, doi: 10.1371/journal.ppat.1002145 (2011).
8. Hsu, J. L. et al. Aspergillus fumigatus invasion increases with progressive airway ischemia. PloS one 8, e77136, doi: 10.1371/journal. pone.0077136 (2013).
9. Takuma, T., Okada, K., Uchida, Y., Yamagata, A. & Sawae, Y. Invasive pulmonary aspergillosis resulting in respiratory failure during neutrophil recovery from postchemotherapy neutropenia in three patients with acute leukaemia. Journal of internal medicine 252, 173-177 (2002).
10. Ben-Ami, R., Lewis, R. E., Leventakos, K. & Kontoyiannis, D. P. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 114, 5393-5399, doi: 10.1182/blood-2009-07-231209 (2009).
11. Blosser, S. J., Merriman, B., Grahl, N., Chung, D. & Cramer, R. A. Two C4-sterol methyl oxidases (Erg25) catalyse ergosterol intermediate demethylation and impact environmental stress adaptation in Aspergillus fumigatus. Microbiology (Reading, England) 160, 2492-2506, doi: 10.1099/mic.0.080440-0 (2014).
12. Chung, D. et al. ChIP-seq and in vivo transcriptome analyses of the Aspergillus fumigatus SREBP SrbA reveals a new regulator of the fungal hypoxia response and virulence. PLoS pathogens 10, e1004487, doi: 10.1371/journal.ppat.1004487 (2014).
13. Grahl, N., Dinamarco, T. M., Willger, S. D., Goldman, G. H. & Cramer, R. A. Aspergillus fumigatus mitochondrial electron transport chain mediates oxidative stress homeostasis, hypoxia responses and fungal pathogenesis. Molecular microbiology 84, 383-399, doi: 10.1111/j.1365-2958.2012.08034.x (2012).
14. Willger, S. D. et al. Dsc orthologs are required for hypoxia adaptation, triazole drug responses, and fungal virulence in Aspergillus fumigatus. Eukaryot Cell 11, 1557-1567, doi: 10.1128/EC.00252-12 (2012).
15. Willger, S. D. et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS pathogens 4, e1000200, doi: 10.1371/journal.ppat.1000200 (2008).
16. Carvalho, A. et al. Infammation in aspergillosis: the good, the bad, and the therapeutic. Annals of the New York Academy of Sciences 1273, 52-59, doi: 10.1111/j.1749-6632.2012.06754.x (2012).
17. Iannitti, R. G. et al. T17/Treg imbalance in murine cystic fbrosis is linked to indoleamine 2, 3-dioxygenase defciency but corrected by kynurenines. American journal of respiratory and critical care medicine 187, 609-620, doi: 10.1164/rccm.201207-1346OC (2013).
18. Kim, B. et al. The Interleukin-1alpha Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines. Frontiers in immunology 4, 391, doi: 10.3389/fmmu.2013.00391 (2013).
19. Eltzschig, H. K. & Carmeliet, P. Hypoxia and infammation. The New England journal of medicine 364, 656-665, doi: 10.1056/NEJMra0910283 (2011).
20. Chen, G. Y. & Nunez, G. Sterile infammation: sensing and reacting to damage. Nature reviews. Immunology 10, 826-837, doi: 10.1038/nri2873 (2010).
21. Ghezzi, P. et al. Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells. Cytokine 3, 189-194 (1991).
22. Frohlich, S., Boylan, J. & McLoughlin, P. Hypoxia-induced infammation in the lung: a potential therapeutic target in acute lung injury? American journal of respiratory cell and molecular biology 48, 271-279, doi: 10.1165/rcmb.2012-0137TR (2013).
23. Bonnett, C. R., Cornish, E. J., Harmsen, A. G. & Burritt, J. B. Early neutrophil recruitment and aggregation in the murine lung inhibit germination of Aspergillus fumigatus Conidia. Infect Immun 74, 6528-6539 (2006).
24. Mehrad, B. et al. CXC chemokine receptor-2 ligands are necessary components of neutrophil-mediated host defense in invasive pulmonary aspergillosis. J Immunol 163, 6086-6094 (1999).
25. Bao, B. et al. In vivo imaging and quantifcation of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. PloS one 7, e50860, doi: 10.1371/journal.pone.0050860 (2012).
26. Mircescu, M. M., Lipuma, L., van Rooijen, N., Pamer, E. G. & Hohl, T. M. Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection. J Infect Dis 200, 647-656 (2009).
27. Robertson, J. B., Stowers, C. C., Boczko, E. & Johnson, C. H. Real-time luminescence monitoring of cell-cycle and respiratory oscillations in yeast. Proc Natl Acad Sci USA 105, 17988-17993 (2008).
28. Cafrey, A. K. et al. IL-1alpha Signaling Is Critical for Leukocyte Recruitment afer Pulmonary Aspergillus fumigatus Challenge. PLoS pathogens 11, e1004625, doi: 10.1371/journal.ppat.1004625 (2015).
29. Jhingran, A. et al. Compartment-Specifc and Sequential Role of MyD88 and CARD9 in Chemokine Induction and Innate Defense during Respiratory Fungal Infection. PLoS pathogens 11, e1004589, doi: 10.1371/journal.ppat.1004589 (2015).
30. Haddad, J. J. Recombinant human interleukin (IL)-1 beta-mediated regulation of hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilization, nuclear translocation and activation requires an antioxidant/reactive oxygen species (ROS)-sensitive mechanism. European cytokine network 13, 250-260 (2002).
31. Hellwig-Burgel, T., Rutkowski, K., Metzen, E., Fandrey, J. & Jelkmann, W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 94, 1561-1567 (1999).
32. Rider, P. et al. The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells. Frontiers in immunology 3, 290, doi: 10.3389/fmmu.2012.00290 (2012).
33. Zhang, W. et al. Evidence that hypoxia-inducible factor-1 (HIF-1) mediates transcriptional activation of interleukin-1beta (IL-1beta) in astrocyte cultures. Journal of neuroimmunology 174, 63-73, doi: 10.1016/j.jneuroim.2006.01.014 (2006).
34. Dinarello, C. A., Simon, A. & van der Meer, J. W. Treating infammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11, 633-652 (2012).
35. de Luca, A. et al. IL-1 receptor blockade restores autophagy and reduces infammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci USA 111, 3526-3531 (2014).
36. Fritzsching, B. et al. Hypoxic Epithelial Necrosis Triggers Neutrophilic Infammation via IL-1 Receptor Signaling in Cystic Fibrosis Lung Disease. American journal of respiratory and critical care medicine, doi: 10.1164/rccm.201409-1610OC (2015).
37. Lee, K. E. & Simon, M. C. SnapShot: Hypoxia-Inducible Factors. Cell 163, 1288-1288 e1281 (2015).
38. Chen, C. L., Chu, J. S., Su, W. C., Huang, S. C. & Lee, W. Y. Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch 457, 53-61, doi: 10.1007/s00428-010-0938-0 (2010).
39. Frangioni, J. V. In vivo near-infrared fuorescence imaging. Curr Opin Chem Biol 7, 626-634 (2003).
40. Zatovicova, M. et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des 16, 3255-3263 (2010).
41. Lou, Y. et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 71, 3364-3376, doi: 10.1158/0008-5472.CAN-10-4261 (2011).
42. Cecchi, A. et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidifcation of hypoxic tumors. J Med Chem 48, 4834-4841 (2005).
43. Desbaillets, I., Diserens, A. C., Tribolet, N., Hamou, M. F. & Van Meir, E. G. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. The Journal of experimental medicine 186, 1201-1212 (1997).
44. Naldini, A., Pucci, A. & Carraro, F. Hypoxia induces the expression and release of interleukin 1 receptor antagonist in mitogen-activated mononuclear cells. Cytokine 13, 334-341, doi: 10.1006/cyto.2001.0842 (2001).
45. Hernandez, M. L. et al. IL-1 receptor antagonist reduces endotoxin-induced airway infammation in healthy volunteers. The Journal of allergy and clinical immunology 135, 379-385, doi: 10.1016/j.jaci.2014.07.039 (2015).
46. Frank, J. A., Pittet, J. F., Wray, C. & Matthay, M. A. Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade. Torax 63, 147-153, doi: 10.1136/thx.2007.079608 (2008).
47. Shepardson, K. M. et al. Myeloid derived hypoxia inducible factor 1-alpha is required for protection against pulmonary Aspergillus fumigatus infection. PLoS pathogens 10, e1004378, doi: 10.1371/journal.ppat.1004378 (2014).
48. Meissner, F. et al. Infammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 116, 1570-1573, doi: 10.1182/blood-2010-01-264218 (2010).
49. Morgenstern, D. E., Giford, M. A., Li, L. L., Doerschuk, C. M. & Dinauer, M. C. Absence of respiratory burst in X-linked chronic granulomatous disease mice leads to abnormalities in both host defense and infammatory response to Aspergillus fumigatus. The Journal of experimental medicine 185, 207-218 (1997).
50. Schappi, M. G., Jaquet, V., Belli, D. C. & Krause, K. H. Hyperinfammation in chronic granulomatous disease and anti-infammatory role of the phagocyte NADPH oxidase. Semin Immunopathol 30, 255-271, doi: 10.1007/s00281-008-0119-2 (2008).
51. van Bruggen, R. et al. Human NLRP3 infammasome activation is Nox1-4 independent. Blood 115, 5398-5400, doi: 10.1182/blood-2009-10-250803 (2010).
52. van de Veerdonk, F. L. et al. Reactive oxygen species-independent activation of the IL-1beta infammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci USA 107, 3030-3033, doi: 10.1073/pnas.0914795107 (2010).
53. Knutsen, A. P. & Slavin, R. G. Allergic bronchopulmonary aspergillosis in asthma and cystic fbrosis. Clinical & developmental immunology 2011, 843763, doi: 10.1155/2011/843763 (2011).
54. Greenberger, P. A. Allergic bronchopulmonary aspergillosis. The Journal of allergy and clinical immunology 110, 685-692 (2002).
55. Knutsen, A. P. et al. Fungi and allergic lower respiratory tract diseases. The Journal of allergy and clinical immunology 129, 280-291; quiz 292-283, doi: 10.1016/j.jaci.2011.12.970 (2012).
56. Kreindler, J. L. et al. Vitamin D3 attenuates T2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fbrosis patients with allergic bronchopulmonary aspergillosis. The Journal of clinical investigation 120, 3242-3254, doi: 10.1172/JCI42388 (2010).
57. Svirshchevskaya, E. V. & Kurup, V. P. Immunotherapy of allergic bronchopulmonary aspergillosis: a clinical and experimental approach. Frontiers in bioscience: a journal and virtual library 8, s92-101 (2003).
58. Bellocchio, S. et al. Immunity to Aspergillus fumigatus: the basis for immunotherapy and vaccination. Medical mycology: ofcial publication of the International Society for Human and Animal Mycology 43 Suppl 1, S181-188 (2005).
59. Buddingh, E. P. et al. Interferon-gamma immunotherapy in a patient with refractory disseminated candidiasis. Pediatr Infect Dis J, doi: 10.1097/INF.0000000000000909 (2015).
60. Delsing, C. E. et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC infectious diseases 14, 166, doi: 10.1186/1471-2334-14-166 (2014).
61. Lehrnbecher, T. et al. Immunotherapy in invasive fungal infection-focus on invasive aspergillosis. Curr Pharm Des 19, 3689-3712 (2013).
62. Kullberg, B. J., van de Veerdonk, F. & Netea, M. G. Immunotherapy: a potential adjunctive treatment for fungal infection. Curr Opin Infect Dis 27, 511-516, doi: 10.1097/QCO.0000000000000105 (2014).
63. Galiger, C. et al. Assessment of efcacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging. Antimicrob Agents Chemother 57, 3046-3059 (2013).
64. Schobel, F. et al. Aspergillus fumigatus does not require fatty acid metabolism via isocitrate lyase for development of invasive aspergillosis. Infect Immun 75, 1237-1244 (2007).
65. Mehrad, B., Moore, T. A. & Standiford, T. J. Macrophage infammatory protein-1 alpha is a critical mediator of host defense against invasive pulmonary aspergillosis in neutropenic hosts. J Immunol 165, 962-968 (2000).
66. Brock, M. et al. Bioluminescent Aspergillus fumigatus, a new tool for drug efciency testing and in vivo monitoring of invasive aspergillosis. Appl Environ Microbiol 74, 7023-7035 (2008).
67. Ntziachristos, V. & Weissleder, R. Experimental three-dimensional fluorescence reconstruction of diffuse media by use of a normalized Born approximation. Opt Lett 26, 893-895 (2001).
68. Ibrahim-Granet, O. et al. Phagocytosis and intracellular fate of Aspergillus fumigatus conidia in alveolar macrophages. Infect Immun 71, 891-903 (2003).
69. Sinha, B. K., Monga, D. P. & Prasad, S. A combination of Gomori-Grocott methenamine silver nitrate and hematoxylene and eosin staining technique for the demonstration of Candida albicans in tissue. Quad Sclavo Diagn 24, 129-132 (1988).
70. Park, S. K. et al. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Mol Cell Biol 23, 4959-4971 (2003).